



NEWS RELEASE

Not for distribution in the United States or to US newswire services

Alpha Cognition Announces Grant of Stock Options

June 8, 2023 – Alpha Cognition Inc. (CSE: ACOG; OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”) announces the grant of stock options pursuant to its stock option plan to certain directors, officers, and employees of the Company to purchase up to an aggregate of 16,190,000 common shares of the Company. The stock options are exercisable at a price of C\$0.22 per share and expire 10 years from the date of grant, subject to certain vesting provisions.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) or any state securities laws, and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.

For further information:

Michael McFadden, CEO
Tel: 1-858-344-4375

info@alphacognition.com
<https://www.alphacognition.com/>

No stock exchange, nor the OTC Markets Group or any stock exchange Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.